AD Pipeline Watch: selectION’s si-544 Performs Well in First-in-human Phase 1b Trial
selectION, Inc.’s si-544 performed well in the first-in-human Phase 1b trial in atopic dermatitis (AD) patients. si-544 is a selectivity-optimized peptide blocking the ion channel Kv1.3. The completed Phase 1b trial was a multi-center, double-blind, placebo-controlled study in patients with mild to severe atopic dermatitis. The trial was designed to evaluate safety, tolerability, and efficacy […]